Aktuellt
SENASTE
Curasight announced positive results from the investor-initiated ph2b study using uPAR-PET in primary brain cancer: 94% (15/16) of glioblastomas in the study were uPAR-PET positive, which in our view is a small de-risking. Together with the recent positive pre-clinical results with uTREAT in glioblastoma, we believe Curasight has enough evidence to further pursue the theranostic approach in glioblastoma. Full results from the study are due to be presented in September 2023.
LÄS MER
